Semnur Pharmaceuticals to go public in SPAC deal of up to $2 billion with Denali Capital

Semnur Pharmaceuticals

02/07/2024 22:48

July 2 (Reuters) - Drug developer Semnur Pharmaceuticals
said on Tuesday it has signed a letter of intent to go public
through a merger with special purpose acquisition company Denali
Capital Acquisition Corp  DECA.O  in a pre-transaction equity
deal valued at up to $2 billion.
    Semnur is a unit of Scilex Holding  SCLX.O .    

 (Reporting by Mariam Sunny in Bengaluru; Editing by Krishna
Chandra Eluri)
 ((Mariam.ESunny@thomsonreuters.com;))